Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Renzhi Wang; Cuiqi Zhou; Ann I McCormack; Adam N Mamelak

doi:10.3389/fendo.2022.868174

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Front Endocrinol (Lausanne). 2022 Mar 9:13:868174. doi: 10.3389/fendo.2022.868174. eCollection 2022.

Authors

Renzhi Wang¹, Cuiqi Zhou², Ann I McCormack³, Adam N Mamelak⁴

Affiliations

¹ Department of Neurosurgery, Peking Union Medical College Hospital (CAMS), Beijing, China.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
³ Department of Endocrinology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
⁴ Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

No abstract available

Keywords: diagnosis; drug resistance; medical therapy; pathogenesis; refractory pituitary adenomas; surgical treatment; temozolomide, targeted and immunotherapy.

Publication types

Editorial